quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:12:41·373d
SECFiling
Vaccinex Inc. logo

SEC Form 10-K filed by Vaccinex Inc.

VCNX· Vaccinex Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • VCNX
    Vaccinex Inc.
    Health Care

Related

  • PR122d
    Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease
  • PR332d
    Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
  • PR368d
    Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
  • SEC388d
    SEC Form NT 10-K filed by Vaccinex Inc.
  • SEC393d
    SEC Form 15-12G filed by Vaccinex Inc.
  • SEC394d
    SEC Form EFFECT filed by Vaccinex Inc.
  • SEC394d
    SEC Form EFFECT filed by Vaccinex Inc.
  • SEC394d
    SEC Form EFFECT filed by Vaccinex Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022